{
    "id": "1091",
    "question": "A 64-year-old man presents to the clinic with easy fatigability and breathlessness when climbing stairs for the last 2 weeks. He also mentions that he occasionally has bouts of cough at night after about 2\u20133 hours of sleep which is relieved when he sits upright. He denies shortness of breath at rest, palpitations, and loss of consciousness. He has had hypertension for the last 20 years and is on antihypertensive medications. On physical examination, his temperature is 36.9\u00b0C (98.4\u00b0F), pulse is 104/min, blood pressure is 122/82 mm Hg, and respirations are 18/min. Chest auscultation reveals crackles over the lung bases bilaterally. Examination of his abdomen reveals mildly tender hepatomegaly. Laboratory investigation results include a hemoglobin of 14.8 g/dL (9.18 mmol/L) and an elevated serum B-type natriuretic peptide. His two-dimensional echocardiogram reveals an enlarged left atrium and an ejection fraction of 55%. Which of the following novel drugs is most likely to benefit the patient in addition to valsartan?",
    "options": {
        "A": "Etanercept",
        "B": "Moxonidine",
        "C": "Sacubitril",
        "D": "Aliskiren"
    },
    "answer": "C",
    "predict": "{\"step_by_step_thinking\": \"To approach this question, let's analyze the patient's symptoms and test results. The patient presents with easy fatigability, breathlessness on exertion, and nocturnal cough, which are classic symptoms of heart failure. The physical examination findings of crackles over the lung bases bilaterally and mildly tender hepatomegaly also support this diagnosis. The laboratory investigation results show an elevated serum B-type natriuretic peptide, which is a biomarker for heart failure. The echocardiogram reveals an enlarged left atrium and a reduced ejection fraction of 55%, indicating left-sided heart failure. The patient is also on antihypertensive medications, which is likely contributing to his symptoms. Given these findings, the patient likely has heart failure with reduced ejection fraction (HFrEF). The question asks which novel drug would benefit the patient in addition to valsartan, which is an angiotensin II receptor blocker (ARB). The options provided are etanercept, moxonidine, sacubitril, and aliskiren. Etanercept is a TNF-alpha inhibitor, moxonidine is an alpha-2 adrenergic agonist, sacubitril is a neprilysin inhibitor, and aliskiren is an angiotensin II receptor antagonist. Sacubitril is often used in combination with valsartan to treat HFrEF, as it enhances the effects of ACE inhibitors or ARBs by inhibiting the breakdown of natriuretic peptides, which is beneficial in heart failure. Therefore, sacubitril is the most likely to benefit the patient in addition to valsartan.\", \"answer_choice\": \"C\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 10.635571956634521
}